SecBot SecBot
SECBOTREPLAY Home › Report › LXRX

LXRX · Q3 loss -$0.03 vs -$0.05 est

Lexicon Pharmaceuticals, Inc. · PRESS-RELEASE filed Nov 5, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 5, 2026 at 07:00 ET

Lexicon reported Q3 2026 net loss of $0.03 per share, narrower than the consensus estimate of -$0.05, on total revenue of $11.3M (including a $10M milestone from Novo), above the $4.1M consensus. The beat was driven by the milestone payment, not product sales; the company highlighted completion of SONATA-HCM enrollment and plans to resubmit the ZYNQUISTA NDA in Q1 2027.

  • Net loss per share -$0.03 vs consensus -$0.05 (beat)
  • Total revenue $11.3M vs consensus $4.1M (beat), driven by $10M Novo milestone
  • INPEFA net product revenue $1.2M, up from $1.0M YoY
  • Cash and investments $183.2M as of Sep 30, 2026, up from $125.2M at Dec 31, 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access